Literature DB >> 27867133

Fiber optic bronchoscopy and remifentanil target-controlled infusion in critically ill patients with acute hypoxaemic respiratory failure: A descriptive study.

Saïda Rezaiguia-Delclaux1, Florent Laverdure2, Talna Kortchinsky2, Léa Lemasle2, Audrey Imbert2, François Stéphan2.   

Abstract

INTRODUCTION: Sedation optimizes patient comfort and ease of execution during fiber optic bronchoscopy (FOB). Our objective was to describe the safety and efficacy of remifentanil-TCI during FOB in non-intubated, hypoxaemic, thoracic surgery ICU patients.
METHODS: Consecutive spontaneously breathing adults requiring FOB after thoracic surgery were included if they had hypoxaemia (PaO2/FiO2<300mmHg or need for non-invasive ventilation [NIV]) and prior FOB failure under topical anaesthesia. The remifentanil initial target was chosen at 1ng/mL brain effect-site concentration (Cet), then titrated to 0.5ng/mL Cet increments according to patient comfort and coughing. Outcomes were patient-reported pain and discomfort (Visual Analogue Scale scores), ventilatory support intensification within 24hours after bronchoscopy, and ease of FOB execution.
RESULTS: Thirty-nine patients were included; all had a successful FOB. Their median PO2/FiO2 before starting FOB was 187±84mmHg and 24 patients received NIV. Median [interquartile range] pain scores were not different before and after FOB (1.0 [0.0-3.0] and 0.0 [0.0-2.0], respectively). Discomfort was reported as absent or minimal by 27 patients (69%; 95% confidence interval [95% CI], 54-81%) and as bothersome but tolerable by 12 patients (31%; 95% CI, 19-46%). Mean FiO2 returned to baseline within 2hours after FOB in 30 patients; the remaining 9 patients (23%; 95% CI, 13-38%) received ventilatory support intensification. Ease of execution was good or very good in 34 patients (87%; 95% CI, 73-94%), acceptable in 4 patients, and poor in 1 patient (persistent cough).
CONCLUSION: Sedation with remifentanil-TCI during FOB with prior failure under topical anaesthesia alone was effective and acceptably safe in non-intubated hypoxaemic thoracic surgery patients.
Copyright © 2016 Société française d'anesthésie et de réanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Fiber optic bronchoscopy; Hypoxaemia; Intensive care unit; Non-invasive ventilation; Remifentanil; Thoracic surgery

Mesh:

Substances:

Year:  2016        PMID: 27867133     DOI: 10.1016/j.accpm.2016.07.004

Source DB:  PubMed          Journal:  Anaesth Crit Care Pain Med        ISSN: 2352-5568            Impact factor:   4.132


  4 in total

1.  Analgosedation during flexible fiberoptic bronchoscopy: comparing the clinical effectiveness and safety of remifentanil versus midazolam/propofol.

Authors:  Hyun Lee; Yeong Hun Choe; Seungyong Park
Journal:  BMC Pulm Med       Date:  2019-12-09       Impact factor: 3.317

2.  Pain and dyspnea control during awake fiberoptic bronchoscopy in critically ill patients: safety and efficacy of remifentanil target-controlled infusion.

Authors:  Margot Caron; Antoine Parrot; Alexandre Elabbadi; Sophie Dupeyrat; Matthieu Turpin; Thomas Baury; Sacha Rozencwajg; Clarisse Blayau; Jean-Pierre Fulgencio; Aude Gibelin; Pierre-Yves Blanchard; Séverine Rodriguez; Daisy Daigné; Marie-Cécile Allain; Muriel Fartoukh; Tài Pham
Journal:  Ann Intensive Care       Date:  2021-03-16       Impact factor: 6.925

3.  Comparison of the Effects of Esketamine/Propofol and Sufentanil/Propofol on the Incidence of Intraoperative Hypoxemia during Bronchoscopy: Protocol for a Randomized, Prospective, Parallel-Group Trial.

Authors:  Xiao Huang; Pan Ai; Changwei Wei; Yuan Sun; Anshi Wu
Journal:  J Clin Med       Date:  2022-08-05       Impact factor: 4.964

4.  Sufentanil target controlled infusion (TCI) versus remifentanil TCI for monitored anaesthesia care for patients with severe tracheal stenosis undergoing fiberoptic bronchoscopy: protocol for a prospective, randomised, controlled study.

Authors:  Wei Wu; Yi Zhou; Yuanjie Zhu; Jianming Liu
Journal:  BMJ Open       Date:  2022-08-30       Impact factor: 3.006

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.